Literature DB >> 28334112

Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients.

Shaogui Wan1,2, Hie-Won Hann3,4, Zhong Ye1, Richard S Hann3, Yinzhi Lai1, Chun Wang1, Ling Li1, Ronald E Myers1, Bingshan Li5, Jinliang Xing6, Hushan Yang1.   

Abstract

Prospective and longitudinal epidemiological evidence is needed to assess the association between telomere length and risk of hepatocellular carcinoma (HCC). In 323 cancer-free Korean-American HBV patients with 1-year exclusion window (followed for >1 year and did not develop HCC within 1 year), we measured the relative telomere length (RTL) in baseline serum DNAs and conducted extensive prospective and longitudinal analyses to assess RTL-HCC relationship. We found that long baseline RTL conferred an increased HCC risk compared to short RTL [hazard ratio (HR) = 4.93, P = 0.0005). The association remained prominent when the analysis was restricted to patients with a more stringent 5-year exclusion window (HR = 7.51, P = 0.012), indicating that the association was unlikely due to including undetected HCC patients in the cohort, thus minimizing the reverse-causation limitation in most retrospective studies. Adding baseline RTL to demographic variables increased the discrimination accuracy of the time-dependent receiver operating characteristic analysis from 0.769 to 0.868 (P = 1.0 × 10-5). In a nested longitudinal subcohort of 16 matched cases-control pairs, using a mixed effects model, we observed a trend of increased RTL in cases and decreased RTL in controls along 5 years of follow-up, with a significant interaction of case/control status with time (P for interaction=0.002) and confirmed the association between long RTL and HCC risk [odds ratio [OR] = 3.63, P = 0.016]. In summary, serum DNA RTL may be a novel non-invasive prospective marker of HBV-related HCC. Independent studies are necessary to validate and generalize this finding in diverse populations and assess the clinical applicability of RTL in HCC prediction.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28334112      PMCID: PMC5963496          DOI: 10.1093/carcin/bgx021

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  51 in total

1.  A strategy for modelling the effect of a continuous covariate in medicine and epidemiology.

Authors:  P Royston
Journal:  Stat Med       Date:  2000-07-30       Impact factor: 2.373

Review 2.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

3.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

4.  Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases.

Authors:  Chi-Pang Wen; Jie Lin; Yi Chen Yang; Min Kuang Tsai; Chwen Keng Tsao; Carol Etzel; Maosheng Huang; Chung Yi Hsu; Yuanqing Ye; Lopa Mishra; Ernest Hawk; Xifeng Wu
Journal:  J Natl Cancer Inst       Date:  2012-10-17       Impact factor: 13.506

5.  Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus.

Authors:  Ichiro Konishi; Yoichi Hiasa; Syuichiro Shigematsu; Masashi Hirooka; Shinya Furukawa; Masanori Abe; Bunzo Matsuura; Kojiro Michitaka; Norio Horiike; Morikazu Onji
Journal:  Liver Int       Date:  2009-04-28       Impact factor: 5.828

6.  Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis.

Authors:  Ruben Raphael Plentz; Young Nyun Park; André Lechel; Haeryoung Kim; Friederike Nellessen; Britta Heike Eva Langkopf; Ludwig Wilkens; Annarita Destro; Barbara Fiamengo; Michael Peter Manns; Massimo Roncalli; Karl Lenhard Rudolph
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

7.  Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis.

Authors:  Stefanie U Wiemann; Ande Satyanarayana; Martina Tsahuridu; Hans L Tillmann; Lars Zender; Juergen Klempnauer; Peer Flemming; Sonia Franco; Maria A Blasco; Michael P Manns; K Lenhard Rudolph
Journal:  FASEB J       Date:  2002-07       Impact factor: 5.191

8.  Measurement of telomere DNA content by dot blot analysis.

Authors:  Masayuki Kimura; Abraham Aviv
Journal:  Nucleic Acids Res       Date:  2011-04-27       Impact factor: 16.971

9.  Blood cell telomere length is a dynamic feature.

Authors:  Ulrika Svenson; Katarina Nordfjäll; Duncan Baird; Laureline Roger; Pia Osterman; Mai-Lis Hellenius; Göran Roos
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

10.  Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients.

Authors:  Hie-Won Hann; Shaogui Wan; Ronald E Myers; Richard S Hann; Jinliang Xing; Bicui Chen; Hushan Yang
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more
  3 in total

1.  Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Martina Mazzon; Elisa Paviati; Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Silvia Giudici; Ricciarda Raffaelli; Fabio Ghezzi; Massimo Franchi; Giuseppe Lippi
Journal:  Pathol Oncol Res       Date:  2020-05-27       Impact factor: 3.201

2.  Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Bella Steiner; Leah M Ferrucci; Lisa Mirabello; Qing Lan; Wei Hu; Linda M Liao; Sharon A Savage; Immaculata De Vivo; Richard B Hayes; Preetha Rajaraman; Wen-Yi Huang; Neal D Freedman; Erikka Loftfield
Journal:  PLoS One       Date:  2020-01-08       Impact factor: 3.240

Review 3.  Revisiting Telomere Shortening in Cancer.

Authors:  Keiji Okamoto; Hiroyuki Seimiya
Journal:  Cells       Date:  2019-01-31       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.